Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
Bristol Myers Squibb and Pfizer have launched an online programme to sell their blockbuster anticoagulant Eliquis directly to patients, following in the footsteps of Eli Lilly and Novo Nordisk in a ...
Crowbar circuits have long been the go-to safeguard against overvoltage conditions, prized for their simplicity and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback